Dr. Denise Scots-Knight

Dr. Denise Scots-Knight

DirectoratMereo BioPharma Group· In proxies 2023–2025

Pay in FY2025-14% from the year before · Mereo BioPharma Group stock -88.1% the same year

Dr. Denise Scots-Knight was paid $2.7M in FY2025 (Dec), down 14%. Mereo BioPharma Group stock fell 88.1% that year.

Pay$100 in the stock at the end of FY22 → $56
Pay is from the Summary Compensation Table of each Mereo BioPharma Group proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Elanco Animal HealthPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  2. Mereo BioPharma GroupPublic company · 3 yr
    • Chief Executive Officer2023 – Present · 3 yrStock in role -46%
  3. Albireo PharmaPublic company
    • Director? – PresentNo stock prices for these years
  4. Idenix PharmaceuticalsPublic company
    • Director? – PresentNo stock prices for these years
  5. ProteolixPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Elanco Animal HealthDirector · 6 yr on the boardIndependentCompensation and Human Capital, Innovation, Science and Technology (Chair)—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?